Univest
Univest
  • Markets

Kilitch Drugs (India) Ltd. (KILITCH): Kilitch Drugs Share Price rises 9.65% as stock trades at Rs 236.90

  • October 5, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Kilitch Drugs Share Price
Kilitch Drugs (India) Ltd. (KILITCH) share price rose to Rs 236.9 today, up 9.65% from the previous close. Market cap was Rs 755.34 crore.

Kilitch Drugs Share Price is at Rs 236.90, up 9.65% today, with market capitalisation at Rs 755.34 Cr.

The latest Univest figures also show that the stock is not trading in isolation. Its valuation sits within a large comparable set in the same industry, which helps frame Kilitch Drugs Share Price News around context rather than speculation. The next checkpoints are the day range, the relationship with the previous close, and whether the company’s fundamentals support the current Kilitch Drugs Share Price level.

Table of Contents

Toggle
  • Kilitch Drugs Share Price Today: Price Action Analysis
  • Kilitch Drugs (India) Ltd. (KILITCH) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Kilitch Drugs
  • About Kilitch Drugs
  • Frequently Asked Questions
    • Why is Kilitch Drugs Share Price rising today?
    • What is Kilitch Drugs Share Price today?
    • What is the market cap of Kilitch Drugs?
    • What does Kilitch Drugs Fundamental Analysis show?
    • How does Kilitch Drugs compare with the industry benchmark?
    • How does Kilitch Drugs compare with listed peers?
    • What are the key price levels for Kilitch Drugs today?
    • Should investors track Kilitch Drugs Share Price on Univest?
  • Track Kilitch Drugs Share Price on Univest

Kilitch Drugs Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 236.9
Previous Close Rs 216.05
Today's Move Rs 20.85 (+9.65%)
Open Rs 226.5
High Rs 248.25
Low Rs 220
Market Capitalisation Rs 755.34 crore
Market Cap Category Micro Cap

Kilitch Drugs (India) Ltd. (KILITCH) rose to Rs 236.9 from the previous close of Rs 216.05, a move of Rs 20.85 or 9.65%. The stock opened at Rs 226.5, reached a high of Rs 248.25, recorded a low of Rs 220.

Kilitch Drugs Share Price is moving higher today after starting above the previous close and trading through a wider intraday range. The stock last traded at Rs 236.90 versus a previous close of Rs 216.05, marking a gain of Rs 20.85 or 9.65%. The day open was Rs 226.50, while the stock touched a high of Rs 248.25 and a low of Rs 220.00. That gives a clear picture of Kilitch Drugs Share Price Today as a strong price rise with a notable spread between the day’s high and low.

For Kilitch Drugs Share Price watchers, the immediate focus is straightforward: the move is real, the range is visible, and the market capitalisation stands at Rs 755.34 Cr. Univest data shows a firm intraday advance, but it does not identify any company-specific trigger. So the right way to read Kilitch Drugs Share Price is as a verified market event first, then as a valuation and business-quality question next. That bridge matters because price action alone does not explain sustainability, which is where Kilitch Drugs Fundamental Analysis becomes relevant.

Kilitch Drugs (India) Ltd. (KILITCH) Fundamental Analysis

Metric Value
Market Capitalisation Rs 755.34 crore
P/E Ratio 25.13x
P/B Ratio 2.69x
ROE 12.26%
ROCE 14.5%
EPS Rs 8.6
Book Value Per Share Rs 80.45
Dividend Yield 0%

Kilitch Drugs (India) Ltd. (KILITCH) fundamental metrics show P/E 25.13x, P/B 2.69x, ROE 12.26%, ROCE 14.5%. These ratios show where the company stands today and are not a call to buy or sell.

Kilitch Drugs (India) Ltd. has a market capitalisation of Rs 755.34 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 25.13x, P/B at 2.69x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.26% and ROCE of 14.5%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 8.6, book value per share of Rs 80.45, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.27x, median ROE of 11.48%, median ROCE of 13.17%. Together they describe the fundamental backdrop without implying a buy or sell view.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 25.13x
Benchmark Median P/E 32.27x
Benchmark Average P/E 48.67x
Benchmark P/E Range 3.58x to 685.2x
Company P/B Ratio 2.69x
Benchmark Median P/B 2.87x
Company ROE 12.26%
Benchmark Median ROE 11.48%
Company ROCE 14.5%
Benchmark Median ROCE 13.17%
Company Market Capitalisation Rs 755.34 crore
Benchmark Median Market Cap Rs 714 crore

Kilitch Drugs (India) Ltd. (KILITCH) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Kilitch Drugs (India) Ltd. (KILITCH) has a P/E ratio of 25.13x, which is below the benchmark median of 32.27x, a difference of -22.13%. A P/E difference of this kind is a reference point rather than a recommendation.

Kilitch Drugs (India) Ltd. (KILITCH) has a ROE of 12.26%, which is above the benchmark median of 11.48%, a difference of +6.79%. Kilitch Drugs (India) Ltd. (KILITCH) has a ROCE of 14.5%, which is above the benchmark median of 13.17%, a difference of +10.1%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Sun Pharmaceutical Industries Ltd. SUNPHARMA 4,34,279.63 35.9 5.02 14.85 19.11
Divi's Laboratories Ltd. DIVISLAB 2,46,737.12 84.35 13.97 16.19 21.51
Torrent Pharmaceuticals Ltd. TORNTPHARM 1,81,129.27 83.05 20.18 26.76 19.27
Zydus Lifesciences Ltd. ZYDUSLIFE 1,14,239.13 25.31 4.24 19.69 21.39
Cipla Ltd. CIPLA 1,08,808.05 32.28 3.1 11.83 16

Kilitch Drugs (India) Ltd. (KILITCH) has a P/E ratio of 25.13x compared with the displayed peer median of 35.9x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.26% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 14.5% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Kilitch Drugs (India) Ltd. (KILITCH) has a market capitalisation of Rs 755.34 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Kilitch Drugs

  • Kilitch Drugs Share Price is up 9.65% today, making the stock notable in current market movers.
  • The latest Univest figures show Kilitch Drugs Share Price trading at Rs 236.90 with market capitalisation of Rs 755.34 Cr.
  • Kilitch Drugs Fundamental Analysis shows PE, PB, ROE and ROCE that can be compared with the same-industry benchmark.
  • Sector analysis places Kilitch Drugs Share Price below the industry median on PE and PB, while ROE and ROCE stay above benchmark medians.
  • Peer comparison shows the company at a much smaller market capitalisation than several large Pharmaceuticals & Drugs names.

About Kilitch Drugs

Kilitch Drugs (India) Ltd. operates in Healthcare and the Pharmaceuticals & Drugs industry. Kilitch Drugs Share Price reflects a business that is valued by the market through earnings, book value and return ratios rather than through income yield, as the latest Univest figures show a dividend yield of 0. The company’s placement in the sector snapshot helps frame Kilitch Drugs Stock Performance against a broad industry group of 204 companies.

For investors following Kilitch Drugs Company News, the useful business lens is simple: the company belongs to a regulated pharmaceutical segment where valuation and return metrics matter alongside daily price movement. Kilitch Drugs Share Price Today can therefore be monitored alongside earnings efficiency, balance-sheet value and sector benchmarks. In practical terms, the company’s market capitalisation of Rs 755.34 Cr positions it in a much smaller bracket than the large listed peers used for comparison, which is why Kilitch Drugs Stock Analysis benefits from both the company-level and the sector-level view.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

Why is Kilitch Drugs Share Price rising today?

Ans. Kilitch Drugs Share Price is up 9.65% today and last traded at Rs 236.90. The price move is confirmed in Univest data; a company-specific reason has not been established.

What is Kilitch Drugs Share Price today?

Ans. Kilitch Drugs Share Price today is Rs 236.90. The stock is higher than its previous close of Rs 216.05, and the day’s move is Rs 20.85 or 9.65%.

What is the market cap of Kilitch Drugs?

Ans. Kilitch Drugs has a market capitalisation of Rs 755.34 Cr. That places Kilitch Drugs Share Price in a smaller company bracket compared with several listed pharmaceuticals peers used in the comparison set.

What does Kilitch Drugs Fundamental Analysis show?

Ans. Kilitch Drugs Fundamental Analysis shows PE at 25.13, PB at 2.69, ROE at 12.26%, ROCE at 14.5%, EPS at Rs 8.6 and book value at Rs 80.45. Dividend yield is 0.

How does Kilitch Drugs compare with the industry benchmark?

Ans. Kilitch Drugs Share Price is backed by a PE below the same-industry median of 32.27 and a PB slightly below the median of 2.87. ROE and ROCE are above the benchmark medians.

How does Kilitch Drugs compare with listed peers?

Ans. Kilitch Drugs Share Price sits on a far smaller market cap than Sun Pharma, Divi's, Torrent, Zydus Lifesciences and Cipla. Its PE and PB are also lower than most of those peers.

What are the key price levels for Kilitch Drugs today?

Ans. Kilitch Drugs Share Price opened at Rs 226.50, touched a high of Rs 248.25 and a low of Rs 220.00. The previous close was Rs 216.05, which helps frame the day’s move.

Should investors track Kilitch Drugs Share Price on Univest?

Ans. Investors tracking Kilitch Drugs Share Price can use Univest to follow live price, valuation ratios, market capitalisation and sector context. It provides a clear way to monitor today’s price action and fundamentals together.

Track Kilitch Drugs Share Price on Univest

Use Kilitch Drugs (India) Ltd. (KILITCH) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Investors can track Kilitch Drugs Share Price on Univest for live price updates, valuation ratios, market capitalisation, 52-week levels and broader market insights. The platform also helps users follow Kilitch Drugs Share Price Today alongside sector benchmarks, peer comparisons and company fundamentals in one place.

For anyone checking Kilitch Drugs Latest News or Kilitch Drugs Stock News, the Univest view keeps the focus on verified market numbers rather than noise. That makes it easier to monitor Kilitch Drugs Share Price Live, compare its valuations and review how the stock stands within Healthcare and Pharmaceuticals & Drugs.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply